Performance of factor IX extended half‐life product measurements in external quality control assessment programs
Open Access
- 20 April 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 18 (8), 1874-1883
- https://doi.org/10.1111/jth.14847
Abstract
No abstract availableFunding Information
- Novo Nordisk
- CSL Behring
- Swedish Orphan Biovitrum
- Pfizer
This publication has 26 references indexed in Scilit:
- Measuring factor IX activity of nonacog beta pegol with commercially available one‐stage clotting and chromogenic assay kits: a two‐center studyJournal of Thrombosis and Haemostasis, 2016
- Laboratory monitoring of new hemostatic agents for hemophiliaSeminars in Hematology, 2016
- Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulatorsHaemophilia, 2015
- Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activityThrombosis and Haemostasis, 2014
- Recombinant factor IX: discrepancies between one‐stage clotting and chromogenic assaysHaemophilia, 2014
- Recommendations on the potency labelling of factor VIII and factor IX concentratesJournal of Thrombosis and Haemostasis, 2013
- Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptideBlood, 2011
- Prolonged activity of factor IX as a monomeric Fc fusion proteinBlood, 2010
- The between-Laboratory Variation of Factor VIII Inhibitor Testing: The Experience of the External Quality Assessment Program of the ECAT FoundationSeminars in Thrombosis and Hemostasis, 2009
- Genetic fusion to albumin improves the pharmacokinetic properties of factor IXThrombosis and Haemostasis, 2009